论文部分内容阅读
溴隐亭对各种原因所致的高泌乳素血症均有疗效,可使90%以上的病人血清泌乳素(prolactin,P-RL)水平显著下降,也可使多数病人瘤体体积缩小。作者联合9个医学中心,筛选27例作长期观察。27例中女16例,男11例。女性平均29岁,男性平均43岁。溴隐亭治疗均持续6个月以上,12例达1年。其中1例治疗9个月后死于与本病无关的转移癌,1例治疗6个月因瘤体过大、体积缩小不明显和长期视野缺损行手术治疗。没有因溴隐亭副反应或肿瘤连续长大而停止治疗者。治疗前测定基础血清 PRL、黄体生成素(LH)和卵泡刺激素(FSH);PRL 和促甲状腺激素(TSH)对促甲状腺素释放激素(TRH)反应;PRL、生长激素(GH)和皮质醇对胰岛素所致低血糖反应;检查视
Bromocriptine is effective for various causes of hyperprolactinemia, which can significantly reduce the level of serum prolactin (P-RL) in more than 90% of the patients and also reduce the volume of tumors in most patients. The authors combined nine medical centers, screening 27 cases for long-term observation. 27 cases of female 16 cases, 11 males. The average woman is 29 years old and the average male is 43 years old. Bromocriptine treatment continued for 6 months or more, 12 cases up to 1 year. Among them, one case died of metastatic carcinoma unrelated to this disease after 9 months of treatment. One case was treated for surgery for 6 months due to the tumor being too large, the volume shrinking insignificantly, and the long-term visual field defect. No treatment due to bromocriptine side effects or tumor growth continued to stop treatment. PRL, LH and FSH were measured before treatment; PRL and thyrotropin (TSH) responses to thyrotropin-releasing hormone (TRH); PRL, growth hormone (GH) and cortisol Insulin-induced hypoglycemia; check as